Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 1-9 |
| Number of pages | 9 |
| Journal | Mycopathologia |
| DOIs | |
| Publication status | Accepted/In press - Oct 9 2017 |
Fingerprint
Keywords
- Boric acid
- Candida albicans
- Candida glabrata
- Drug resistant
- Organoboron
Cite this
Boric Acid and Commercial Organoboron Products as Inhibitors of Drug-Resistant Candida albicans. / Larsen, Bryan; Petrovic, Marija; DeSeta, Francesco.
In: Mycopathologia, 09.10.2017, p. 1-9.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Boric Acid and Commercial Organoboron Products as Inhibitors of Drug-Resistant Candida albicans
AU - Larsen, Bryan
AU - Petrovic, Marija
AU - DeSeta, Francesco
PY - 2017/10/9
Y1 - 2017/10/9
N2 - © 2017 Springer Science+Business Media B.V. Clinical use of boric acid as a topical antifungal in women who have failed standard antifungal therapy with azole drugs has been used sporadically for decades. Our previous in vitro work showing inhibition of Candida albicans growth was conducted on clinical isolates without antifungal drug susceptibility profiling. Here, we report that boric acid restricts growth of drug-resistant Candida albicans and inhibits hyphal growth and diminishes cell volume. The availability of over-the-counter organoboron compounds intended for use as oral nutritional supplements led us to determine if these also were inhibitory toward resistant Candida and show here that they also possess antifungal activity. Candida glabrata was also found to be inhibited by boric acid and organoboron compounds. Further development of organoboron compounds as topical therapeutics is of potential value.
AB - © 2017 Springer Science+Business Media B.V. Clinical use of boric acid as a topical antifungal in women who have failed standard antifungal therapy with azole drugs has been used sporadically for decades. Our previous in vitro work showing inhibition of Candida albicans growth was conducted on clinical isolates without antifungal drug susceptibility profiling. Here, we report that boric acid restricts growth of drug-resistant Candida albicans and inhibits hyphal growth and diminishes cell volume. The availability of over-the-counter organoboron compounds intended for use as oral nutritional supplements led us to determine if these also were inhibitory toward resistant Candida and show here that they also possess antifungal activity. Candida glabrata was also found to be inhibited by boric acid and organoboron compounds. Further development of organoboron compounds as topical therapeutics is of potential value.
KW - Boric acid
KW - Candida albicans
KW - Candida glabrata
KW - Drug resistant
KW - Organoboron
UR - http://www.scopus.com/inward/record.url?scp=85030853205&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030853205&partnerID=8YFLogxK
U2 - 10.1007/s11046-017-0209-6
DO - 10.1007/s11046-017-0209-6
M3 - Article
AN - SCOPUS:85030853205
SP - 1
EP - 9
JO - Mycopathologia
JF - Mycopathologia
SN - 0301-486X
ER -